Sanofi seeks to expand UK inhalables site with an eye on CMO business

By Gareth Macdonald contact

- Last updated on GMT

Sanofi site in Cheshire
Sanofi site in Cheshire
Sanofi wants to expand its inhalable drug production site in Cheshire, UK to increase capacity for both its own brand drug production operations and its contract manufacturing business.

The Paris-headquartered drugmaker lodged planning applications​ with Cheshire East Council last week, explaining that it wants to revamp the site in response to greater demand for its products and for its contract manufacturing services.

Sanofi wants to expand the site’s manufacturing, warehousing and stability testing laboratories, alter some of its internal roads to accommodate heavy goods vehicles and construct new reception facilities, a canteen and a staff carpark.

Design consultant How Planning set out Sanofi’s motivation for the expansion in a report assessing the potential economic impact, explaining that customer demand for inhalable drugs was the key driver.

The Holmes Chapel site is currently experiencing a period of operational growth associated with natural business growth and the new business line of researching, manufacturing and developing 3rd party products within the facility.

The report adds that: “The primary objective of the sites expansion and development is to create additional operational capacity, office floor space and infrastructure to accommodate the increased number of personnel working on site and continue to meet demand for the company’s products​.”

News of the proposed expansion comes just weeks after Sanofi CEO Olivier Brandicourt outlined plans for a major corporate restructuring. 

The plan - full details of which are expected to be released next January - will see Sanofi establish five worldwide business units: general medicines and emerging markets, specialty care, diabetes and cardiovascular, Sanofi Pasteur for vaccines, and Merial for animal health.

At present the company has seven “growth platforms​” structured differently according to country, including consumer healthcare and Genzyme, for rare diseases.

Related news

Show more

Related products

show more

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Related suppliers

Follow us


View more